NONALCOHOLIC STEATOHEPATITIS (NASH)
Clinical trials for NONALCOHOLIC STEATOHEPATITIS (NASH) explained in plain language.
Never miss a new study
Get alerted when new NONALCOHOLIC STEATOHEPATITIS (NASH) trials appear
Sign up with your email to follow new studies for NONALCOHOLIC STEATOHEPATITIS (NASH), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a single pill tackle both fatty liver and diabetes?
Disease control CompletedThis trial tests an experimental oral drug called HTD1801 in adults with nonalcoholic steatohepatitis (NASH), a serious liver condition, along with liver fibrosis and type 2 diabetes or prediabetes. Participants receive either HTD1801 or a placebo to see if the drug can improve l…
Matched conditions: NONALCOHOLIC STEATOHEPATITIS (NASH)
Phase: PHASE2 • Sponsor: HighTide Therapeutics (Hong Kong) Limited • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New shot shows promise for fatty liver disease in early trial
Disease control CompletedThis study tested a drug called BOS-580 (efimosfermin) in 231 obese adults with or at risk for NASH, a serious fatty liver disease. Participants received either the drug or a placebo as a shot under the skin. The main goal was to check safety and side effects. The trial is now co…
Matched conditions: NONALCOHOLIC STEATOHEPATITIS (NASH)
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC